5 Results for "

reactive protein test

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "reactive protein test" in MCE Product Catalog:

Cat. No.: HY-121360
CAS No.: 143545-90-8
Cylindrospermopsin, a cyanotoxin, is a polycyclic uracil derivative containing guanidine and sulfate groups, which can inhibit protein synthesis and covalently modify DNA or RNA. Cylindrospermopsin induces hepatocellular hypertrophy, renal cellular hypertrophy, intracellular reactive oxygen species (ROS), DNA strand breaks, mitochondrial hyperpolarisation, ultrastructural damage, and altered gene expression in liver, kidney, and intestinal cells. Cylindrospermopsin can be used in research including hepatocellular carcinoma and water quality testing .
loading...
    loading...
Cat. No.: HY-153489
CAS No.: 827355-42-0
Synonyms: ISIS-CRPRx
ISIS 329993 (ISIS-CRPRx) is an antisense oligonucleotide targeting to C-reactive protein (CRP). ISIS-CRPRx has been tested in a rodent model of rheumatoid arthritis (RA) and was shown to improve the clinical signs of arthritis
loading...
    loading...
Cat. No.: HY-153489A
Synonyms: ISIS-CRPRx sodium
ISIS 329993 sodium is an antisense oligonucleotide targeting to C-reactive protein (CRP). ISIS-CRPRx sodium has been tested in a rodent model of rheumatoid arthritis (RA) and was shown to improve the clinical signs of arthritis
loading...
    loading...
Cat. No.: HY-19086
CAS No.: 122454-69-7
Target:  

COX Lipoxygenase

Research Areas:  

Inflammation/Immunology

SKF-105809 is a dual-action inhibitor of lipoxygenase and COX. SKF-105809 inhibits edema and inflammatory cell infiltration in mouse models of ear, paw, and peritoneum inflammation. SKF-105809 inhibits the production of relevant acute-phase reactive proteins in a mouse model of arthritis. SKF-105809 exhibits analgesic activity in a mouse abdominal contraction test and inhibits ulceration. SKF-105809 can be used in research on inflammatory and immune system diseases such as peritonitis and arthritis .
loading...
    loading...
Cat. No.: HY-L076
641 compounds

Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug.

DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver.

MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 641 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.